<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937998</url>
  </required_header>
  <id_info>
    <org_study_id>PRP-21</org_study_id>
    <nct_id>NCT04937998</nct_id>
  </id_info>
  <brief_title>PRP Versus HA IN OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT</brief_title>
  <official_title>THE USE OF FRESH PRP VS HA IN THE TREATMENT OF OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the 12-month clinical outcomes of patients with&#xD;
      patellofemoral osteoarthritis undergoing infiltrative treatment with fresh PRP and HA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      166 patients affected by patellofemoral osteoarthritis will be included in a double-blinded&#xD;
      RCT. In this study one group of patients will be treated with 1 intra-articular injection of&#xD;
      PRP (treatment arm) and one group will be treated with 1 intra-articular injection of HA&#xD;
      (control arm). Patients will be followed-up with clinical evaluation at baseline and at&#xD;
      2.6.12 and 24 months. Questionnaires will be administered for clinical evaluations during the&#xD;
      follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a double-blinded RCT in which one group of patients will be treated with 1 intra-articular injection of fresh PRP, and one group will be treated with 1 intra-articular injection of HA.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>This is a double-blinded randomized controlled trial with 1:1 allocation.Patient blinding will be provided during the injection treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>KOOS-Pain Score</measure>
    <time_frame>12 months</time_frame>
    <description>KOOS-Pain Score is referred to a subscale of pain composed by 9 items. The score range considerate is 0-100.The score uses a 5-point Likert scale and each question is assigned a score from 0 to 4, where 0 indicates &quot;no pain&quot; and 4 &quot;severe level of pain&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IKDC-Subjective Score</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathologies. All questions examines 3 categories: symptoms, sports activity, and knee function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS-Pain Score</measure>
    <time_frame>baseline, 2 month, 6 months , 24 months follow-up</time_frame>
    <description>KOOS-Pain Score is referred to a subscale of pain composed by 9 items. The score range considerate is 0-100.The score uses a 5-point Likert scale and each question is assigned a score from 0 to 4, where 0 indicates &quot;no pain&quot; and 4 &quot;severe level of pain&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>VAS is a visual analogue scale consisting of a range scale (10 cm length), the ends of which correspond to &quot;no pain&quot; and &quot;the strongest pain imaginable&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-VAS</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>EQ-VAS Is a visual analog scale that has a range of scores from 0 (worst imaginable health condition) to 100 (best imaginable health condition).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D (EuroQoL) Current Health Assessment</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>EQ-5D is useful to evaluate the quality life of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tegner Activity Level Scale</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>Tegner activity level scale allows to know the level of physical activity carried out by the patients. All patients will indicate the type of sporting activity performed and its frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective parameters- Range of Motion</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>Evaluation of the Range of Motion for comparative analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective parameters - Circumferences</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>Bilateral trans- and supra- patellar circumferences measurement for comparative analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Acceptable Symptom State (PASS)</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>A tool to assess patient satisfaction in consideration of their current degree of pain, function, and daily activity. Patients can express if their state of health will be satisfying, answering &quot;yes&quot; or &quot;no.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Kujala Anterior Knee Pain Scale (AKPS)</measure>
    <time_frame>baseline, 2 month, 6 months, 12 months , 24 months follow-up</time_frame>
    <description>It's a 100-point scale consisting of 13 items with a score ranging from 5 to 10 points per item. A score of 0 points indicates the most severe limitation, while a score of 100 points indicates a normal situation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Patellofemoral Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Autologous PRP injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of patients will be treated with single intra-articular injection of Autologous PRP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HA injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of patients will be treated with single intra-articular injection of Hyaluronic Acid (HA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous PRP injection</intervention_name>
    <description>Patients will be treated with a single injection of Autologous PRP (5 ml) in the knee joint affected by patellofemoral osteoarthritis</description>
    <arm_group_label>Autologous PRP injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HA injection</intervention_name>
    <description>Patients will be treated with a single injections of Hyaluronic Acid (5 ml) in the knee joint affected by patellofemoral osteoarthritis</description>
    <arm_group_label>HA injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 30 and 65;&#xD;
&#xD;
          2. Signs and symptoms of isolated patellofemoral osteoarthritis present in one or both&#xD;
             knees;&#xD;
&#xD;
          3. Radiographic signs of isolated patellofemoral osteoarthritis (according to Iwano et al&#xD;
             stage 1-3 classification) or chondropathy (assessed on MRI) with K-L grade of the&#xD;
             other compartments ≤ 2. [PMID: 2302884 - PMID: 27979409] ;&#xD;
&#xD;
          4. Hemoglobin &gt; 11 g/dl; Platelet count &gt; 150,000 plt/mm3 (Recently performed CBC exam);&#xD;
&#xD;
          5. No clinically significant electrocardiographic alterations (Recently performed ECG).&#xD;
&#xD;
          6. Ability and consent of patients to actively participate in clinical follow-up;&#xD;
&#xD;
          7. Signature of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable to express consent;&#xD;
&#xD;
          2. Patients who have undergone intra-articular infiltration of another substance within&#xD;
             the previous 6 months;&#xD;
&#xD;
          3. Patients undergoing knee surgery within the previous 12 months;&#xD;
&#xD;
          4. Patients with malignant neoplasms;&#xD;
&#xD;
          5. Patients with rheumatic diseases;&#xD;
&#xD;
          6. Patients with diabetes;&#xD;
&#xD;
          7. Patients with hematologic diseases (coagulopathies);&#xD;
&#xD;
          8. Patients on anticoagulant-antiaggregant therapy;&#xD;
&#xD;
          9. Patients with thyroid metabolic disorders;&#xD;
&#xD;
         10. Patients abusing alcoholic beverages, drugs or medications;&#xD;
&#xD;
         11. Body Mass Index &gt; 35;&#xD;
&#xD;
         12. Patients who have taken NSAIDs in the 3 days prior to blood draw;&#xD;
&#xD;
         13. Patients with cardiovascular disease for which a 60 mL blood draw would be&#xD;
             contraindicated;&#xD;
&#xD;
         14. Patients with a recently performed blood test with Hb&lt; 11 g/dl and Platelets &lt; 150,000&#xD;
             plt/mm3.&#xD;
&#xD;
         15. Previous treatment of patellar dislocation&#xD;
&#xD;
         16. Iwano score of grade 4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Di Martino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Licciardi, MSc</last_name>
    <phone>0516366567</phone>
    <email>roberta.licciardi@ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Di Martino, MD</last_name>
    <email>alessandro.dimartino@ior.it</email>
  </overall_contact_backup>
  <reference>
    <citation>Di Martino A, Di Matteo B, Papio T, Tentoni F, Selleri F, Cenacchi A, Kon E, Filardo G. Platelet-Rich Plasma Versus Hyaluronic Acid Injections for the Treatment of Knee Osteoarthritis: Results at 5 Years of a Double-Blind, Randomized Controlled Trial. Am J Sports Med. 2019 Feb;47(2):347-354. doi: 10.1177/0363546518814532. Epub 2018 Dec 13.</citation>
    <PMID>30545242</PMID>
  </reference>
  <reference>
    <citation>Everts PA, Knape JT, Weibrich G, Schönberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006 Jun;38(2):174-87. Review.</citation>
    <PMID>16921694</PMID>
  </reference>
  <reference>
    <citation>Cavallo C, Filardo G, Mariani E, Kon E, Marcacci M, Pereira Ruiz MT, Facchini A, Grigolo B. Comparison of platelet-rich plasma formulations for cartilage healing: an in vitro study. J Bone Joint Surg Am. 2014 Mar 5;96(5):423-9. doi: 10.2106/JBJS.M.00726.</citation>
    <PMID>24599205</PMID>
  </reference>
  <reference>
    <citation>deDeugd CM, Pareek A, Krych AJ, Cummings NM, Dahm DL. Outcomes of Patellofemoral Arthroplasty Based on Radiographic Severity. J Arthroplasty. 2017 Apr;32(4):1137-1142. doi: 10.1016/j.arth.2016.11.006. Epub 2016 Nov 15.</citation>
    <PMID>27979409</PMID>
  </reference>
  <reference>
    <citation>Assirelli E, Filardo G, Mariani E, Kon E, Roffi A, Vaccaro F, Marcacci M, Facchini A, Pulsatelli L. Effect of two different preparations of platelet-rich plasma on synoviocytes. Knee Surg Sports Traumatol Arthrosc. 2015 Sep;23(9):2690-703. doi: 10.1007/s00167-014-3113-3. Epub 2014 Jun 19.</citation>
    <PMID>24942296</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRP</keyword>
  <keyword>HA</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Autologous PRP</keyword>
  <keyword>PRP injection</keyword>
  <keyword>HA injection</keyword>
  <keyword>injection treatment</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Platelet rich plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

